EuroPCR 2018 | Compare-Acute: FFR or Primary Angioplasty at a 2-Year Follow-Up After Complete Revascularization

Recent studies in patients undergoing acute myocardial infarction showed that a complete revascularization strategy in an acute or subacute setting, whether it be guided through angiography (PRAMI, CvLPRIT) or fractional flow reserve (FFR) (PRIMULTI, COMPARE-ACUTE), improves the combined endpoint of major adverse cardiac events (MACE) when compared with treatment of the culprit artery only. Based on these results, the European Society of Cardiology (ESC) modified the recommendations included in its guidelines on ST-segment elevation myocardial infarction.

EuroPCR 2018 | Compare-Acute: FFR o angioplastia primaria en el seguimiento a 2 años de la revascularización completa Now, we have the 2-year results of the COMPARE-ACUTE trial, which included patients undergoing an ST-segment elevation myocardial infarction with successful primary angioplasty of the culprit artery and other coronary lesions. These subjects were randomized to complete revascularization guided through FFR or only culprit-artery revascularization.

 

This study included 885 patients (295 randomized to complete FFR-guided revascularization vs. 590 randomized to culprit-artery revascularization only).


Read also: EuroPCR 2018 | BIO-RESORT: Polymer vs. Bioresorbable Polymer; Have We Reached a Plateau with DES?


At two years, the complete FFR-guided revascularization arm showed significant reduction in combined events (12.2% vs. 26.8%; hazard ratio [HR]: 0.41; 95% confidence interval [CI]: 0.29 to 0.59; p < 0.001). This difference was mainly driven by higher rates of repeat revascularization in the culprit-artery-only arm.

 

Such reduction persisted over time and does not seem to depend on the presence of lesions in 2 or 3 vessels.

 

Original title: Compare-Acute: Two-Year Follow-Up of Complete FFR-Guided PCI vs. Infarct-Artery-Only PCI in Multivessel STEMI Patients.

Presenter: Pieter Smits.

 

Compare-Acute


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Patients at High Risk of Bleeding After Coronary Angioplasty: Are Risk Assessment Tools ARC-HBR and PRECISE-DAPT Useful?

Patients undergoing coronary stenting typically receive dual antiplatelet therapy (DAPT) for 6 to 12 months, consisting of a P2Y12 receptor inhibitor and aspirin. While DAPT...

ACC 2025 | WARRIOR: Ischemia in Women with Non-Obstructive Coronary Artery Disease

Approximately half of all women with symptomatic ischemia who undergo coronary angiography are found to have non-obstructive coronary artery disease ((ischemia and non-obstructive coronary...

ACC 2025 | FLAVOUR II: Angiography-Derived FFR-Guided vs. IVUS-Guided PCI

Physiological assessment is effective when it comes to decision-making for percutaneous coronary intervention (PCI). However, despite the available evidence, its use remains limited. AngioFFR...

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Patients at High Risk of Bleeding After Coronary Angioplasty: Are Risk Assessment Tools ARC-HBR and PRECISE-DAPT Useful?

Patients undergoing coronary stenting typically receive dual antiplatelet therapy (DAPT) for 6 to 12 months, consisting of a P2Y12 receptor inhibitor and aspirin. While DAPT...

ACC 2025 | WARRIOR: Ischemia in Women with Non-Obstructive Coronary Artery Disease

Approximately half of all women with symptomatic ischemia who undergo coronary angiography are found to have non-obstructive coronary artery disease ((ischemia and non-obstructive coronary...

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...